Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
AstraZeneca amyloidosis drug fails to reduce mortality in ph. 3
Plans for an amyloidosis blockbuster look further out of reach after the anti-fibril antibody failed to reduce deaths and hospitalizations.
James Waldron
Jul 16, 2025 4:28am
AstraZeneca’s $1.3B hypertension med bet pays off with ph. 3 win
Jul 14, 2025 4:09am
Eolas regains opioid use disorder drug abandoned by AstraZeneca
Jul 10, 2025 9:33am
AstraZeneca’s Alexion pens $825M AAV capsid pact with JCR
Jul 9, 2025 4:52am
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Fierce Pharma
Summit in high-stakes deal talks with AstraZeneca: Bloomberg
Jul 7, 2025 10:45am